BLRX Company Profile and Key Details
NASDAQ : BLRX
BioLineRx
$2.89
-0.0368-1.26%
Open: 2:39 PM71.42
BESG ScoreESG Rating
Price Chart
Stock Price Today
BioLineRx Ltd. (BLRX) stock declined over -1.26%, trading at $2.89 on NASDAQ, down from the previous close of $2.93. The stock opened at $2.96, fluctuating between $2.89 and $3.02 in the recent session.
Stock Snapshot
2.93
Prev. Close
12.59M
Market Cap
2.89
Day Low
-1.56
P/E Ratio
-1.85
EPS (TTM)
-0.32
Cash Flow per Share
2.96
Open
4.35M
Number of Shares
3.02
Day High
99.44%
Free Float in %
0.18
Book Value
4.15K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 19, 2026 | 2.73 | 2.93 | 2.73 | 2.93 | 2.41K |
| Aug 18, 2026 | 2.67 | 2.85 | 2.67 | 2.85 | 20.35K |
| Aug 17, 2026 | 2.76 | 2.86 | 2.60 | 2.64 | 19.65K |
| Aug 14, 2026 | 2.70 | 2.76 | 2.69 | 2.76 | 3.08K |
| Aug 13, 2026 | 2.69 | 2.87 | 2.65 | 2.72 | 4.89K |
| Aug 12, 2026 | 2.72 | 3.00 | 2.69 | 2.69 | 11.29K |
| Aug 11, 2026 | 2.73 | 2.85 | 2.73 | 2.78 | 4.59K |
| Aug 10, 2026 | 2.66 | 2.85 | 2.66 | 2.71 | 8.81K |
| Aug 07, 2026 | 2.85 | 2.85 | 2.71 | 2.71 | 6.69K |
| Aug 06, 2026 | 2.84 | 2.88 | 2.71 | 2.79 | 15.64K |
| Aug 05, 2026 | 2.82 | 2.97 | 2.72 | 2.72 | 4.63K |
| Aug 04, 2026 | 2.81 | 2.82 | 2.71 | 2.76 | 3.96K |
| Aug 03, 2026 | 2.78 | 2.88 | 2.63 | 2.66 | 5.07K |
| Jul 31, 2026 | 2.73 | 2.82 | 2.65 | 2.82 | 9.65K |
| Jul 30, 2026 | 2.75 | 2.77 | 2.68 | 2.70 | 7.12K |
| Jul 29, 2026 | 2.81 | 2.89 | 2.75 | 2.75 | 5.8K |
| Jul 28, 2026 | 2.84 | 2.91 | 2.81 | 2.81 | 16.04K |
| Jul 27, 2026 | 2.87 | 2.92 | 2.82 | 2.82 | 5.12K |
| Jul 24, 2026 | 2.86 | 3.04 | 2.82 | 2.82 | 2.69K |
| Jul 23, 2026 | 2.82 | 3.04 | 2.82 | 2.86 | 8.02K |
Contact Details
About Company
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Company Information
| Employees | 22 |
| Beta | 0.71 |
| Sales or Revenue | $4.80M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
39.87+4.02%
argenx SE$1,032.86REGN30.6+3.78%
Regeneron Pharmaceuticals, Inc.$840.84VRTX23.87+4.52%
Vertex Pharmaceuticals Incorporated$552.06MDGL15.79+3.01%
Madrigal Pharmaceuticals, Inc.$540.16UTHR10.87+2.10%
United Therapeutics Corporation$529.14PRAX16.35+4.42%
Praxis Precision Medicines, Inc.$386.19ONC7.71+2.09%
BeOne Medicines AG$376.86KRYS10.52+3.16%
Krystal Biotech, Inc.$343.34KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83LGND3.12+1.08%
Ligand Pharmaceuticals Incorporated$290.71Company Overview
BioLineRx Ltd. (NASDAQ:BLRX) closed at $2.78 USD, losing -$0.15 (-5.12%) from the previous close of $2.93. The stock is currently mid-range between its 52-week high and low $2.15 and $4.56. With a market capitalization of about $12.10 million, BioLineRx Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.71). Key stats such as the average daily volume over the past year has been around 22.32 thousand shares, volume is running light vs its 52-week average. Headquartered in Hevel Modi'in, HM, BioLineRx Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Philip A. Serlin, the company employs approximately 22 people and listed since July 27, 2011. BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology.
Technical Performance
BLRX has shown mixed momentum, losing -1.05% over the past week and -24.13% over the past quarter, though year-to-date performance is up 2.17%. Short-term trend indicators are mixed aligned (SMA20 -2.09%, SMA50 -1.99%, SMA200 -21.62%). The stock’s 14-day RSI is 47.37 (neutral), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -62.93% below its high and over 25.21% above its low. Average 10-day trading volume of 9.38 thousand shares is below the 3-month average of 22.95 thousand, indicating normal recent market interest.
Valuation Metrics
BioLineRx Ltd. trades at a P/E ratio of -1.38, slightly below the S&P 500 average, with a price-to-sales ratio of 9.05 and a price-to-book ratio of 0.78 suggesting the stock is closer to book value. The P/FCF stands at -1.62, also above market averages.
Dividend & Fair Value
BioLineRx Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.50. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
BioLineRx Ltd. generated EPS of -$1.37 over the past year. Five-year average earnings growth is 46.37%. Wall Street analysts project EPS growth of 57.36% annually over the next five years. BioLineRx Ltd. earnings surprise history is a mixed track record. The quarter that ended May 27, 2026, missed forecasts by -65.38%. The prior quarter beat by -32.0%. Over the last six quarters, Apple has recorded several small beats. These include -265.48% in May 27, 2025.
Shareholding & Insider Activity
BioLineRx Ltd. has 4.35 million shares outstanding. The public float is 4.16 million shares, elevated short interest at 3.36% of float. This equals 145.93 thousand shares. The short ratio is 5.84 days. Institutional investors hold 0.47% of the float. Insiders own 3.91%.
Financial & Profitability Overview
On valuation metrics, BioLineRx trades at a P/E of -1.38, P/S of 9.05 and P/B of 0.78. The current ratio is 1.58 and quick ratio is 1.43. Operationally, the company’s inventory turnover is 0.16 and cash conversion cycle is -2336.37 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.54, supported by a cash flow-to-debt ratio of -0.86.
Quarterly Financial Highlights
The company ended the quarter with $42.99M in cash and short-term investments, a total debt of $11.59M, and net debt of $7.34M. Total assets were $63.93M, with equity of $13.22M. Financials further reflected weakness, with operating cash flow of - $22.61M, free cash flow of - $22.91M, and capital expenditures of - $297.00K.
Price Forecast & Outlook
Our AI price prediction model suggests that BioLineRx Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.44%, with price expected at $2.80 by September 02, 2026, within a range of $2.73 to $2.86 3-Month Outlook: Projected fall of -50.85%, reaching $1.44 by November 17, 2026, with a range of $1.21 to $1.60. 1-Year Outlook: Projected loss of -11.6%, with price at $2.59 by August 19, 2027, within a range of $0.00 to $2.49.
Key Takeaways
BioLineRx Ltd. (NASDAQ:BLRX) shares are flat 2.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BioLineRx Ltd. trading at a premium to the broader market with a P/E of -1.38. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.14, suggesting 314.33% upside. Our AI forecast model points to short-term weakness (-4.44% over two weeks), a medium-term fall (-50.85% over three months), and a longer-term loss (-11.6% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current BioLineRx Ltd. (BLRX) stock price?
BioLineRx Ltd. (NASDAQ: BLRX) stock price is $2.89 in the last trading session. During the trading session, BLRX stock reached the peak price of $3.02 while $2.89 was the lowest point it dropped to. The percentage change in BLRX stock occurred in the recent session was -1.26% while the dollar amount for the price change in BLRX stock was - $0.04.
BLRX's industry and sector of operation?
The NASDAQ listed BLRX is part of Biotechnology industry that operates in the broader Healthcare sector. BioLineRx Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BLRX?
Dr. Abi Vainstein-Haras M.D.
Chief Medical Officer
Mr. Adam Janoff Esq.
Gen. Counsel & Head of Compliance
Ms. Mali Zeevi CPA, CPA
Chief Financial Officer
Advocate Norman Kotler
Internal Enforcement Officer, Gen. Counsel and Corporation Sec.
Ms. Holly W. May M.B.A.
Pres of BioLineRx USA
Mr. Raziel Fried
Treasurer & Budgetary Control Director
Dr. Ella Sorani
Chief Devel. Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Executive Officer
Mr. John Lacey
Head of Corporation Communications & Investor Relations
Ms. Jael Birenberg M.Sc.
Senior Director & Head of RA, QA and PhV
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.
Head of BD & Strategic Advisor
Ms. Liron Shemesh-Darvish M.B.A., Ph.D.
Senior Director & Head of Preclinical Devel.
Chief Medical Officer
Mr. Adam Janoff Esq.
Gen. Counsel & Head of Compliance
Ms. Mali Zeevi CPA, CPA
Chief Financial Officer
Advocate Norman Kotler
Internal Enforcement Officer, Gen. Counsel and Corporation Sec.
Ms. Holly W. May M.B.A.
Pres of BioLineRx USA
Mr. Raziel Fried
Treasurer & Budgetary Control Director
Dr. Ella Sorani
Chief Devel. Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Executive Officer
Mr. John Lacey
Head of Corporation Communications & Investor Relations
Ms. Jael Birenberg M.Sc.
Senior Director & Head of RA, QA and PhV
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.
Head of BD & Strategic Advisor
Ms. Liron Shemesh-Darvish M.B.A., Ph.D.
Senior Director & Head of Preclinical Devel.
How BLRX did perform over past 52-week?
BLRX's closing price is 36.28% higher than its 52-week low of $2.15 where as its distance from 52-week high of $4.56 is -35.75%.
How many employees does BLRX have?
Number of BLRX employees currently stands at 22.
Link for BLRX official website?
Official Website of BLRX is: https://www.biolinerx.com
How do I contact BLRX?
BLRX could be contacted at phone 972 864 29100 and can also be accessed through its website. BLRX operates from Modiâin Technology Park, Hevel Modi'in, HM 7177871, Israel.
How many shares of BLRX are traded daily?
BLRX stock volume for the day was 4.15K shares. The average number of BLRX shares traded daily for last 3 months was 22.33K.
What is the market cap of BLRX currently?
The market value of BLRX currently stands at $12.59M with its latest stock price at $2.89 and 4.35M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep